BriOri BioTech is developing a platform topical chemistry that will allow for a pipeline of opiate-free topical pain medications. The platform chemistry is targeted to develop safer, more effective, longer lasting topical formulations with APIs proven to be effective. Their novel topical medications will finally give suffering patients an effective option without the risks of dependency and addiction caused by opioids. BriOri’s lead asset, a topical formula for osteoarthritis, has demonstrated safety and efficacy in pre-clinical models and the company plans to advance to human clinical trials in 2022. BriOri is also working on a next-generation medication combination with the potential to neutralize mild-to-moderate neuropathic pain and render opioid use for such indications obsolete.
